KRIBIOLISA™ Golimumab (SIMPONI) ELISA

Enzyme Immunoassay for the quantitative determination of Golimumab in serum, plasma and cell culture supernatant. Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a proinflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Golimumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Golimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Golimumab antibody is pipetted and incubated. After washing microwells in order to removeany non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Golimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.